BHCM
NKTR icon

Brevan Howard Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Brevan Howard Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
21,918
-26,556
-55% -$1.94M 0.01% 854
2026
Q1 		$3.49M Buy
+48,474
New +$2.76M 0.03% 358
2025
Q4 		– Sell
-4,109
Closed -$234K – 2133
2025
Q3 		$234K Buy
+4,109
New +$136K ﹤0.01% 1685

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brevan Howard Capital Management's NKTR Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Nektar Therapeutics (NKTR) stake by 55% in Q2 2026, selling an estimated $1.94M and leaving 21,918 shares worth $1.53M. The position accounts for 0.01% of the portfolio, ranked #854.

Brevan Howard Capital Management first reported a position in NKTR in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.49M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Brevan Howard Capital Management held 21,918 shares of Nektar Therapeutics worth $1.53M as of Q2 2026.
  • Brevan Howard Capital Management sold 26,556 Nektar Therapeutics shares in Q2 2026, an estimated $1.94M.
  • Nektar Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #854 holding.
  • Brevan Howard Capital Management first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Brevan Howard Capital Management's Nektar Therapeutics position peaked at $3.49M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.